Notice Type
Departmental
Notice Title

Renewal of Provisional Consent to the Distribution of a New Medicine

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the schedule hereto:
Schedule
Product: Codalax Forte
Active Ingredient(s): Poloxamers 200mg/mL
Danthron 15mg/mL
Dosage Form: Oral suspension
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer(s): Douglas Manufacturing, div. Douglas Pharmaceuticals Limited, Lincoln, Auckland
Regent Laboratories Limited, North Acton, London, England
Universal Products Limited, Lytham, Lancashire, England
Condition: This medicine may only be used for the prevention or treatment of constipation in the terminally ill.
Note: This consent is valid for 2 years from 30 July 2000.
Product: Codalax
Active Ingredient(s): Poloxamers 40mg/mL
Danthron 5mg/mL
Dosage Form: Oral suspension
New Zealand Sponsor: Douglas Pharmaceuticals Limited
Manufacturer(s): Douglas Manufacturing, div. Douglas Pharmaceuticals Limited, Lincoln, Auckland
Regent Laboratories Limited, North Acton, London, England
Universal Products Limited, Lytham, Lancashire, England
Condition: This medicine may only be used for the prevention or treatment of constipation in the terminally ill.
Note: This consent is valid for 2 years from 30 July 2000.
Product: Invirase
Active Ingredient(s): Saquinavir mesylate 228.7mg equivalent to 200mg Saquinavir free base
Dosage Form: Capsule
New Zealand Sponsor: Roche Products (New Zealand) Limited
Manufacturer(s): F Hoffmann-La Roche AG, Basle, Switzerland
Hoffmann-La Roche Inc, Nutley, New Jersey, United States of America
Note: This consent is valid for 2 years from 6 June 2000.
Dated this 27th day of April 2000.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).